


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 1. (Currently amended): A method for preventing a viral infection in a
2 mammal, said method comprising: administering a pharmaceutically effective amount of a
3 liposomal formulation to said mammal, wherein said liposomal formulation comprises:

- 4 a) a lipid vesicle; and
5 b) a ~~fatty acid monoglyceride~~ an active agent for preventing said viral
6 infection of formula:



7
8 wherein R¹ or R² is ~~[[a]] an C₂-C₁₈-alkyl octyl~~ group and the other is hydrogen;

9 and,

10 wherein said viral infection is caused by ~~an enveloped virus~~ HSV or HIV.

2-5. (Canceled)

1 6. (Withdrawn): The method of claim 1, wherein said enveloped virus is
2 selected from the group consisting of VSV, VV, MV, HSV, and HIV.

1 7. (Withdrawn): The method of claim 1, wherein said infection is a bacterial
2 infection.

1 8. (Withdrawn): The method of claim 7, wherein said bacterial infection is
2 selected from the group consisting of Gonorrhea and Chlamydia.

1 **9.** (Withdrawn): The method of claim **1**, wherein said infection is a parasitic
2 protozoan infection.

1 **10.** (Withdrawn): The method of claim **7**, wherein said protozoa is *Giardia*
2 *lamblia*.

1 **11.** (Withdrawn): The method of claim **1**, wherein said formulation is selected
2 from the group consisting of a topical formulation, an oral formulation, a nasal formulation, an
3 ophthalmic formulation, a rectal formulation, vaginal formulation, and parenteral formulation.

1 **12.** (Withdrawn): A liposomal formulation comprising:
2 a) a lipid vesicle; and
3 b) at least one single chain lipid active agent.

1 **13.** (Withdrawn): The liposomal formulation of claim **12**, wherein said active
2 agent is selected from the group consisting of a monoglyceride, a fatty acid, a lysophospholipid,
3 and a combination thereof.

1 **14.** (Withdrawn): The liposomal formulation of claim **13**, wherein said active
2 agent is a monoglyceride.

1 **15.** (Withdrawn): The liposomal formulation of claim **14**, wherein said
2 monoglyceride is a monoalkyletherglyceride with a number of carbon atoms in the alkyl moiety
3 portion being from about 2 to about 18.

1 **16.** (Withdrawn): The liposomal formulation of claim **15**, wherein said
2 monoglyceride is selected from the group consisting of 1 O-alkyl-sn-glycerol, 2-O-alkyl-sn-
3 glycerol, and a mixture thereof.

1 **17.** (Withdrawn): The liposomal formulation of claim **16**, wherein said
2 monoglyceride is 1-O-octyl-sn-glycerol, 2-O-octyl-sn-glycerol, and a mixture thereof.

1 **18.** (Withdrawn): The liposomal formulation of claim **14**, wherein said
2 monoglyceride is a single chain fatty acid monoglycerides with a number of carbon atoms in the
3 fatty acid moiety portion being from about 6 and about 12.

1 **19.** (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle comprises a phospholipids.

1 **20.** (Withdrawn): The liposomal formulation of claim **19**, wherein said
2 phospholipid is phosphatidylcholine.

1 **21.** (Withdrawn): The liposomal formulation of claim **20**, wherein said lipid
2 vesicle further comprises a diluent selected from the group consisting of a co-solvent, a buffer
3 solution, an anti-oxidant, a preservative, a thickening agent and a mixture thereof.

1 **22.** (Withdrawn): The liposomal formulation of claim **21**, wherein said co-
2 solvent comprises propylene glycol, ethanol, water or mixtures thereof.

1 **23.** (Withdrawn): The liposomal formulation of claim **21**, wherein said anti-
2 oxidant comprises vitamin E acetate.

1 **24.** (Withdrawn): The liposomal formulation of claim **21**, wherein said
2 preservative comprises methylparaben, propylparaben or mixtures thereof.

1 **25.** (Withdrawn): The liposomal formulation of claim **21**, wherein said
2 thickening agent comprises Carbopol, Crothix or mixtures thereof.

1 **26.** (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle is unilamellar.

1 **27.** (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle is multilamellar.

1 **28.** (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle is oligolamellar.

1 **29.** (Withdrawn): The liposomal formulation of claim **12**, wherein said lipid
2 vesicle comprises a co-lipid.

1 **30.** (Withdrawn): The liposomal formulation of claim **29**, wherein said co-
2 lipid is selected from the group consisting of a cholesterol, a phospholipid, a cationic lipid, an
3 anionic lipid, and a combination thereof.

1 **31.** (Withdrawn): The liposomal formulation of claim **30**, wherein said
2 cationic lipid is selected from the group consisting of stearyl-amine, DC-Chol, DOTAP, and a
3 combination thereof.

1 **32.** (Withdrawn): The liposomal formulation of claim **30**, wherein said
2 anionic lipid is selected from the group consisting of PS, PG, and a combination thereof.

1 **33.** (Withdrawn): The liposomal formulation of claim **12**, wherein said
2 formulation is a topical formulation.

1 **34.** (Withdrawn): The liposomal formulation of claim **33**, wherein said
2 topical formulation is selected from the group consisting of cream, a gel, a lotion, a suppository,
3 a fluid suspension, and a paste.

1 **35.** (Withdrawn): The liposomal formulation of claim **12**, wherein said active
2 agent is encapsulated by the lipid vesicle.

1 **36.** (Withdrawn): A pharmaceutical composition comprising:
2 a pharmaceutical excipient; and
3 a liposomal formulation comprising a lipid vesicle and at least one single chain
4 lipid active agent.

1 **37.** (Withdrawn): The composition of claim **36**, wherein said excipient
2 comprises an antioxidant, a co-solvent, a preservative, a flavoring agent, vitamin, a thickening
3 agent, a buffer solution, a wetting agent, an emulsifying agent, a suspending agent, a sweetening
4 agent, a flavoring agent, a perfuming agent or mixtures thereof.

1 **38.** (Withdrawn): The method of claim **1**, wherein said C₂-C₁₈ alkyl group is a
2 C₆-C₁₂ alkyl group.

1 **39.** (Currently amended): The method of claim ~~[[38]]~~ **1**, wherein said fatty
2 ~~acid monoglyceride~~ active agent is 1-O-octyl-sn-glycerol ~~or 2-O-octyl-sn-glycerol~~.

1 **40.** (Withdrawn): The method of claim **39**, wherein said enveloped virus is
2 selected from the group consisting of VSV, VV, MV, HSV, and HIV.

1 **41.** (Withdrawn): The method of claim **40**, wherein said formulation is
2 selected from the group consisting of a topical formulation, an oral formulation, a nasal
3 formulation, an ophthalmic formulation, a rectal formulation, vaginal formulation, and parenteral
4 formulation.

1 **42.** (New): The method of claim **1**, wherein said active agent is 2-O-octyl-sn-
2 glycerol.